A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
- Disease/Condition
- Type 2 Diabetes Mellitus
- Drug/Device/Intervention
- Cagrilintide
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- Novo Nordisk A/S
- Location
- Birmingham,Birmingham,Pelham,Phoenix,Phoenix,Little Rock,Banning,Chula Vista,Concord,Escondido,Gardena,La Mesa,La Mesa,Loma Linda,Mission Hills,Palm Springs,Panorama City,San Diego,Santa Ana,Toluca La, Argentina,Australia,Brazil,Bulgaria,Canada,China,Colombia,Croatia,Czech,Denmark,Finland,Germany,Gree
- Phase
- Phase 3
- Start date
- Sep 27, 2023
- End date
- Jan 14, 2026
- Enrollment
- 2700 participants
CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg versus 1.0 mg): Change in glycated haemoglobin (HbA1c),CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg versus 1.0 mg): Relative change in body weight
The study will look at how well CagriSema helps people lower their blood sugar and body
 weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and
 cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide,
 when they are taken alone. CagriSema will also be compared to a dummy medicine without any
 active ingredient. The study will be done in participants who have type 2 diabetes.
 Participants will take the study medicine together with the current diabetes medicine
 (metformin with or without an SGLT2 inhibitor).
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06065540
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06065540 through Pure Global AI's free database. This Phase 3 trial is sponsored by Novo Nordisk A/S and is currently Recruiting. The study focuses on Type 2 Diabetes Mellitus. Target enrollment is 2700 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.